Radoslaw S. Laufer

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1<i>R</i>,2<i>S</i>)-2-(3-((<i>E</i>)-4-(((<i>cis</i>)-2,6-Dimethylmorpholino)methyl)styryl)-1<i>H</i>-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Peter B. Sampson, Yong Liu, Bryan Forrest et al. · Journal of Medicinal Chemistry · 2014 · 166 citations · Full text

<i>C</i>₂-Symmetric Planar Chiral Ferrocene Diamides by (−)-Sparteine-Mediated Directed <i>ortho</i>-Lithiation. Synthesis and Catalytic Activity

Radoslaw S. Laufer, Ulrich Veith, Nicholas J. Taylor et al. · Organic Letters · 2000 · 117 citations

Cross-coupling Reaction, Engineering, Asymmetric Alkylation +11

The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3<i>H</i>]indol]-2′(1′<i>H</i>)-ones as Orally Bioavailable Antitumor Agents

Peter B. Sampson, Yong Liu, Narendra Kumar Patel et al. · Journal of Medicinal Chemistry · 2014 · 109 citations

Pharmaceutical Science, Polo-like Kinase Family, Compound 18 +22

Diazo Group Electrophilicity in Kinamycins and Lomaiviticin A:  Potential Insights into the Molecular Mechanism of Antibacterial and Antitumor Activity

Radoslaw S. Laufer, Gary I. Dmitrienko · Journal of the American Chemical Society · 2002 · 90 citations

Antitumor Activity, Antibiotic Adjuvant, Antimicrobial Chemotherapy +16

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Yong Liu, Radoslaw S. Laufer, Narendra Kumar Patel et al. · ACS Medicinal Chemistry Letters · 2016 · 78 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Drug Target +14